These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 18600564)

  • 1. Integrase inhibitors for the treatment of HIV infection.
    Pace P; Rowley M
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel integrase inhibitors for HIV.
    Prada N; Markowitz M
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
    Summa V; Petrocchi A; Bonelli F; Crescenzi B; Donghi M; Ferrara M; Fiore F; Gardelli C; Gonzalez Paz O; Hazuda DJ; Jones P; Kinzel O; Laufer R; Monteagudo E; Muraglia E; Nizi E; Orvieto F; Pace P; Pescatore G; Scarpelli R; Stillmock K; Witmer MV; Rowley M
    J Med Chem; 2008 Sep; 51(18):5843-55. PubMed ID: 18763751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies.
    Burger DM
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1151-60. PubMed ID: 20701552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J; Dong BJ
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of 2-pyrrolinones as inhibitors of HIV-1 integrase.
    Ma K; Wang P; Fu W; Wan X; Zhou L; Chu Y; Ye D
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6724-7. PubMed ID: 21996518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Integrase inhibitor: raltegravir also as first line therapy].
    MMW Fortschr Med; 2010 Apr; 152(17):48. PubMed ID: 20509261
    [No Abstract]   [Full Text] [Related]  

  • 11. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
    Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
    Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to HIV-1 integrase inhibitors: A structural perspective.
    Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
    Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
    Kravchenko AV
    Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raltegravir as first integrase inhibitor in an HIV-infection].
    Papendorp SG; Brinkman K
    Ned Tijdschr Geneeskd; 2009 Jan; 153(5):166-7. PubMed ID: 19256240
    [No Abstract]   [Full Text] [Related]  

  • 16. Study explains Isentress' excellent resistance profile.
    Proj Inf Perspect; 2008 Dec; (47):3. PubMed ID: 19226674
    [No Abstract]   [Full Text] [Related]  

  • 17. The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    Buzón MJ; Dalmau J; Puertas MC; Puig J; Clotet B; Martinez-Picado J
    AIDS; 2010 Jan; 24(1):17-25. PubMed ID: 19770695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raltegravir: the first HIV type 1 integrase inhibitor.
    Hicks C; Gulick RM
    Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.
    Rowley M
    Prog Med Chem; 2008; 46():1-28. PubMed ID: 18381123
    [No Abstract]   [Full Text] [Related]  

  • 20. Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.
    Roquebert B; Blum L; Collin G; Damond F; Peytavin G; Leleu J; Matheron S; Chêne G; Brun-Vézinet F; Descamps D;
    AIDS; 2008 Oct; 22(15):2045-6. PubMed ID: 18784469
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.